CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology
The U.S. Food and Drug Administration (FDA) plays a critical role in overseeing the safety and efficacy of investigational drugs before they enter clinical trials. The FDA’s guidance document, “Investigational New Drug (IND) Applications,” provides essential recommendations for submitting IND applications, ensuring compliance with regulatory standards. This article highlights key takeaways from the guidance and […]
Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers
The U.S. Food and Drug Administration (FDA) continues to evolve its regulatory framework to incorporate advancements in digital health technologies (DHTs). The FDA’s guidance document, “Digital Health Technologies for Drug Development,” provides crucial recommendations for the use of digital tools in clinical trials and regulatory submissions. This article highlights key takeaways from the guidance and […]
Bioresearch Monitoring Technical Conformance Guide
The U.S. Food and Drug Administration (FDA) plays a pivotal role in establishing regulatory standards for drug development and approval. The FDA’s guidance document, “Clinical Trial Endpoints for Drug Development,” provides essential recommendations for selecting appropriate endpoints in clinical trials. This article highlights key takeaways from the guidance and its implications for pharmaceutical companies, researchers, […]
Control of Nitrosamine Impurities in Human Drugs
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring that the pharmaceutical supply chain remains resilient and that drug shortages are minimized. The FDA’s guidance document, “Manufacturing, Supply Chain, and Drug Shortages,” provides essential recommendations for drug manufacturers to maintain product availability and manage disruptions effectively. This article highlights key takeaways […]
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies
The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring that new drugs and biological products meet safety, efficacy, and quality standards before they reach the market. The FDA’s guidance document, “Benefit-Risk Assessment for New Drug and Biologic Approvals,” provides a structured framework for evaluating the benefits and risks associated with these […]
Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases
In August 2024, the U.S. Food and Drug Administration (FDA) released the final guidance document titled “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases.” This guidance aims to assist sponsors in identifying optimized dosages for oncology drugs and biological products during clinical development, prior to submitting approval […]
M12 Drug Interaction Studies
In August 2024, the U.S. Food and Drug Administration (FDA) released the M12 Drug Interaction Studies Guidance for Industry, developed in collaboration with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guidance aims to harmonize approaches in designing, conducting, and interpreting enzyme- or transporter-mediated in vitro and clinical […]
FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products
In August 2024, the U.S. Food and Drug Administration (FDA) released the “FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products.” This technical specifications document provides detailed instructions for the electronic submission of Individual Case Safety Reports (ICSRs) in the E2B(R3) format to the FDA’s Adverse […]
CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)
The U.S. Food and Drug Administration (FDA) has released the updated Guidance for Industry #100, titled “Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances, and Excipients (Revision 2), VICH GL18(R2).” This revision provides comprehensive recommendations for controlling residual solvents in veterinary medicinal products, ensuring animal safety and product quality. Understanding Residual Solvents in […]